Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

BACKGROUND: The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the combination of UMEC with the long-acting β(2)-agonist (LABA) vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD) in the US and EU. They are not indicated for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F, Niewoehner, Dennis, Brooks, Jean, O’Dell, Dianne, Church, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113670/
https://www.ncbi.nlm.nih.gov/pubmed/25015176
http://dx.doi.org/10.1186/1465-9921-15-78

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113670/
https://www.ncbi.nlm.nih.gov/pubmed/25015176
http://dx.doi.org/10.1186/1465-9921-15-78

Ejemplares similares